- Home
- SERV vs SCPH Comparison
SERV vs SCPH Comparison
Compare SERV & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- SCPH
- Stock Information
- Founded
- SERV 2017
- SCPH 2013
- Country
- SERV United States
- SCPH United States
- Employees
- SERV N/A
- SCPH N/A
- Industry
- SERV Industrial Specialties
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- SCPH Health Care
- Exchange
- SERV Nasdaq
- SCPH Nasdaq
- Market Cap
- SERV 338.7M
- SCPH 274.7M
- IPO Year
- SERV N/A
- SCPH 2017
- Fundamental
- Price
- SERV $8.00
- SCPH $3.46
- Analyst Decision
- SERV Strong Buy
- SCPH Strong Buy
- Analyst Count
- SERV 3
- SCPH 2
- Target Price
- SERV $14.67
- SCPH $15.00
- AVG Volume (30 Days)
- SERV 6.4M
- SCPH 470.9K
- Earning Date
- SERV 11-07-2024
- SCPH 11-13-2024
- Dividend Yield
- SERV N/A
- SCPH N/A
- EPS Growth
- SERV N/A
- SCPH N/A
- EPS
- SERV N/A
- SCPH N/A
- Revenue
- SERV $1,679,360.00
- SCPH $30,278,000.00
- Revenue This Year
- SERV $901.23
- SCPH $195.62
- Revenue Next Year
- SERV $675.79
- SCPH $145.07
- P/E Ratio
- SERV N/A
- SCPH N/A
- Revenue Growth
- SERV 692.32
- SCPH 303.87
- 52 Week Low
- SERV $1.77
- SCPH $3.08
- 52 Week High
- SERV $30.00
- SCPH $6.71
- Technical
- Relative Strength Index (RSI)
- SERV N/A
- SCPH 30.73
- Support Level
- SERV N/A
- SCPH $4.00
- Resistance Level
- SERV N/A
- SCPH $4.60
- Average True Range (ATR)
- SERV 0.00
- SCPH 0.23
- MACD
- SERV 0.00
- SCPH -0.07
- Stochastic Oscillator
- SERV 0.00
- SCPH 25.25
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an advanced, AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.